Cancer Early Diagnostic Solutions

MastoCheck is a blood test that can easily screen for breast cancer at an early stage. Breast cancer is diagnosed early by substituting the quantitative values of three types of protein biomarkers in the blood, which are closely related to breast cancer, into a unique, patented algorithm.
An innovative and convenient test method that detects early breast cancer with an accuracy of 92% (based on the patent) by using only a very small amount of blood.
Bertis has developed multiple markers that can detect early breast cancer with an accuracy of 92% through identification of multiple proteins that are expressed sensitively in early-stage breast cancer and combination of certain proteins that demonstrated high accuracy
and reproducibility among these combinations.

DEVELOPMENT PROCESS:
- MASTOCHECK was developed by a team led by Professor Dong-Young Noh, a world-renowned authority on breast cancer, of Seoul National University.
- After analyzing approximately 600,000 proteins and selecting 3 markers exhibiting optimal accuracy,
the highest accuracy was obtained by adding Bertis�¢?? own algorithm that enhances accuracy.
- After several years of repeated validation work, a medical device product license was obtained from the MFDS in January 2019. To date (as of September 2023), MASTOCHECK has been introduced to about 400 hospitals and screening institutions nationwide, with priority given to large screening institutions.

Application
Suspected case test in epidemic area
Early test of fever clinic and CDC
Screening of primary medical institutions
Inspection of floating population in public areas
Performance Characterisitics
Sample tyep: nasal swab Time to result: 15-20 minutes
Sensitivity: 97.70% Specificity: 99.84% Accuracy:98.97%
Layperson study statistics
99.84% of non-professionals carried out the test without requiring assistance
99.82% of different types of results were interpreted correctly.

Parameters:
A Short Test Time: 15 mintues
B Accuracy: More than 98.1%
C Sensitivity: 96.4% Specificity: 100%
D Easy operation: Nasal Swab
E One Step solution
F Lower cost with high efficiency
G Package: 1 Test/Kit, 5 Tests/Kit, 25 Tests/Kit
H It can detection for Omicron Virus

Price and Minumum Quantity
Price FOB in USD: 1.5Minimum Order Qty: 500000 Pieces
Production Capacity: 100 Million Boxes Per WeekPackaging: 1,5,20,25,40,100,200 Pcs Per Box
Sample: Available. Sample Cost Born By Buyer
Product Model And Origin
Brand: jwfModel: jwf01
Seller Code: Jwf
Standards: Ce
Competitive Advantages
Lower cost with high efficiency
Detection for omicron virus
Easy operation
Short test time
Other Details
Omicron covid test kit
Covid test kit
Omicron test card
Covid test card

Cancer Diagnostic Device

PANCCHECK is a blood test solution that enables early diagnosis of pancreatic cancer with 94% accuracy is under development.

PANCCHECK DEVELOPMENT PROCESS:
While effective early diagnostic methods for pancreatic cancer are currently lacking, BERTIS is developing a technology that enables early diagnosis of pancreatic cancer with a small blood sample.

Through research, we have identified 10 protein biomarkers as a diagnostic marker panel for pancreatic cancer. Following algorithm development and validation, we have uncovered a combination of markers that demonstrates a high accuracy of 98% and is applicable in clinical settings.

It is a breakthrough and powerful diagnostic system for use by doctors and hospitals. It offers early and multiple disease detection capabilities, reducing diagnoses procedures to a minimum. Due to the complexity of our body systems, diagnosing internal disorders can be difficult. So physicians often refer patients for a series of further tests before drawing final conclusions.

Medex testÖ is presently in use in:
Primary and outpatient care / services
Emergency wards
Cardiology
Oncology
Hospital departments of internal medicine
Gastroenterology
DoctorÆs practices
Occupational and medical insurance groups
What is
Medex testÖ?
The governing principle behind this new technology is based on information from special zones on the body called dvzÆs (dermatome- visceral zones). Measurements taken from the hands and feet are expressions of the skinÆs electrical conductivity and resistance, and reflect changes in normal organ function. It is principally designed to detect early cancers and tumors of the colon, liver, stomach and most other organs.

6kg

We are the authorized distributing partner of the South Korean diagnostic manufacturer BioTNS.

Our role is to distribute in South Korea and overseas the Covid-19
RT-PCR PNA kits.

1 kit allows you to test 100 patients.

- CE approved
- US FDA approved

Contact us to receive your quotation.

One Step Fecal Occult Blood (FOB) Rapid Test Cassette (Feces)
Cat. No.: RH0301T
INTENDED USE
The One-Step Fecal Occult Blood (FOB) Diagnostic Kit is a qualitative detection of human occult blood in feces forself-testing.
PRINCIPLE
The One-Step Fecal Occult Blood (FOB) Diagnostic Kit is an immunochromatographic sandwich method, which employ two specific monoclonal antibodies to selectively identify hemoglobin in test samples. The result is very specific, and easier to interpret than those of guaiac-based test. The sensitivity is very high with the ability to detect 200ng/ml hemoglobin in feces. In addition, the accuracy of the test is not affected by interfering substances, and dietary restriction is not necessary.
STORAGE
The kits should be stored at temperature 4-30�°C, the sealed pouch for the duration of the shelf life (24 months). Do the test in 1 hour after open the pouch.
WARNING AND PRECAUTIONS
1. For in vitro diagnostic use only.
2. Do not use kit beyond the expiration date.
3. Patient specimens may contain infectious agents and should be handled as though capable of transmitting disease. Wear disposable gloves throughout the specimen collection and assay procedures.
4. The test device should not be reused.
REAGENTS AND MATERIALS PROVIDED
1. One pouched cassette with desiccant.
2. One operating Instruction
MATERIALS REQUIRED BUT NOT PROVIDED
1. Clock or Timer
SPECIMEN COLLECTION AND PREPARATION
1. Collect stool sample by using the sample collection device provided.
2. Unscrew the top of the sample collection device, take out the sample collection stick, and collect the sample by dipping the stick into 3 different places of the stool sample.
3. Put the sample collection stick back in the sample collection device and screw together tightly.
4. If the sample cannot be tested on the day of collection, store the stool sample at 4C. Bring the specimen to room temperature before testing.
ASSAY PROCEDURE
1. Remove the test device from foil pouch by tearing along the notch.
2. Specimen collection. Please see also SAMPLE COLLECTION AND PREPARATION
3. Shake the sample collection device several times.
4. Holding the sample collection device upright, carefully unscrew the tip of collection device.
5. Squeeze 2-3 drops of the sample solution on the test sample pad.
6. Read the test results in 5 minutes.
INTERPRETATION OF RESULTS
Negative: Only one colored band appears on the control region (C). No colored band in the test region (T).
Positive: In addition to the control band (C), a distinct colored band also appears in the test region (T).
Invalid: If no bands appear, or a test band appears without a control band, the test should be repeated using a new test device.

Companion Diagnostics (CDx) provide a companion diagnostic solution through pathway analysis based on RNA and protein quantification information respective to subtypes from each diseases.

For precision medicines developed based on multi-omics analysis, biomarkers can be used to identify target patients in advance. Global pharmaceutical companies are active in the use of companion diagnostics as a key strategic tool in clinical development programs.

PASS provides solutions for the entire process from discovery of drug candidates to non-clinical to clinical trials through pan-omics technology.

Bertis has array of innovative and reliable technology to increase the safety and efficacy of an investigational drug across the clinical research landscape, including solutions for the discovery of biomarkers for companion diagnostics and the determination of clinical targets through functional analysis.